Protagonist Therapeutics (PTGX) Amortization of Deferred Charges (2019 - 2021)

Protagonist Therapeutics has disclosed Amortization of Deferred Charges across 3 years of filings, most recently posting $491000.0 for Q3 2021.

• Amortization of Deferred Charges for Q3 2021 came in at $491000.0, up 10.59% year-over-year; the trailing twelve-month figure through Sep 2021 was $1.8 million (up 2.59% YoY), and the FY2020 annual result was $1.8 million, down 0.95% from the prior year.
• Amortization of Deferred Charges came in at $491000.0 for Q3 2021 at Protagonist Therapeutics, up from $443000.0 in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $491000.0 in Q3 2021 to a low of $443000.0 in Q2 2020.
• The 3-year median for Amortization of Deferred Charges is $444000.0 (2019), against an average of $449545.5.
• Across the five-year window, Amortization of Deferred Charges retreated 3.27% in 2020 and increased 10.59% in 2021, its largest moves.
• Protagonist Therapeutics' Amortization of Deferred Charges stood at $445000.0 in 2019, then retreated by 0.22% to $444000.0 in 2020, then increased by 10.59% to $491000.0 in 2021.
• The last three Amortization of Deferred Charges figures came in at $491000.0 (Q3 2021), $443000.0 (Q2 2021), and $444000.0 (Q1 2021), per Business Quant data.